This reflects the impact of our efficiency measures and disciplined expense management across R&D and G&A while we continue to invest in sales and marketing to drive long-term growth.
May 5, 2026 / receipt
This reflects the impact of our efficiency measures and disciplined expense management across R&D and G&A while we continue to invest in sales and marketing to drive long-term growth.
May 5, 2026 / receipt, needs a key / Richie Jane, CFO | earnings call 2026-05-05 | transcript 5fb0601b-aa26-4328-bb66-f6b783ef862e | chars 9322-9505 | segment 9
I think our path to profitability between growth in software and drug discovery as well as expense management over the three-year window, that was all based on our cash position at the time. This is just upside to that. And we will, once we receive the cash, kind of revisit if anything changes. But I would expect our three-year outlook at the time to be unchanged.
May 5, 2026 / receipt, needs a key / Richie, CFO | earnings call 2026-05-05 | transcript 5fb0601b-aa26-4328-bb66-f6b783ef862e | chars 28887-29253 | segment 29
Sales and marketing expense for Q4 was 10 million compared to 9.4 million in Q4 2022. The increase was mainly due to increased staff and associated expenses. Compared to Q3, sales and marketing expense increased by 9%, based on headcount and year-end incentive compensation. For the full year sales and marketing expense of 37 million compared to 31 million in 2022, the increase of 21% was driven by higher headcount and associated expenses, as well as increased travel.
Feb 28, 2024 / receipt, needs a key / Jeff Porges, CFO | earnings call 2024-02-28 | transcript 6bb3f3a5-ecc7-44a0-b0f0-e364a717660e | chars 15838-16309 | segment 16
Travel and lease expenses have also increased, and we expect quarterly G&A to be relatively stable through the balance of 2023.
May 4, 2023 / receipt, needs a key / Jeff Porges, CFO | earnings call 2023-05-04 | transcript 24cb78e6-ebf1-4687-b840-6cbcc2e8691e | chars 10651-10778 | segment 11
The increase was mainly due to higher staffing and increases in associated expenses as travel resumed compared to 2021.
Feb 28, 2023 / receipt, needs a key / Jeff Porges, CFO | earnings call 2023-02-28 | transcript 73ca6163-cfae-4c4e-bcfe-7ad6636acaa4 | chars 9696-9815 | segment 9
Travel costs have also increased compared to 2021.
Feb 28, 2023 / receipt, needs a key / Jeff Porges, CFO | earnings call 2023-02-28 | transcript 73ca6163-cfae-4c4e-bcfe-7ad6636acaa4 | chars 13417-13467 | segment 13
And the part of that result was a reduction in the software, the sales and marketing effort in terms of expenses during the year, travel, conferences, things of that nature.
Mar 4, 2020 / receipt, needs a key / CEO, CEO | earnings call 2020-03-04 | transcript d29b5f5e-193f-43b2-9c36-4e836b337eba | chars 37771-37944 | segment 38
| Geoffrey Porges | Executive Vice President and Chief Financial Officer | - | receipt |
| Jeff Porges | CFO | - | receipt |
| Karen Akinsanya | President, Head of Therapeutics R&D and | - | receipt |
| Rami Fareed | CEO | - | receipt |
| Richie Jain | Chief Financial Officer | receipt | |
| Richie Jane | CFO | - | receipt |
| 2025-05-20 | Executive Vice President and Chief Financial Officer, appointed | sec_8k |
| 2022-08-18 | Executive Vice President and Chief Financial Officer, appointed | sec_8k |